Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eciskafusp Alfa + BCG in BCG-Unresponsive NMIBC
NCT06816017Phase 1Withdrawn
- Sponsor
- Roche
- Start
- Jun 2025
- Primary completion
- Oct 2028
- Modality
- Immunomodulatory ADCs, Fc-Fusion Proteins
- Countries
- 6
01
Overview
Phase 1, open-label trial of eciskafusp alfa in non-muscle-invasive bladder cancer (NMIBC) (3 arms), sponsored by Roche. Primary endpoints: Number of Participants With Adverse Events (AEs), Number of Participants With Dose Limiting Toxicities (DLTs) and 2 more. Planned start Jun 2025; status: withdrawn.
02
Drugs
eciskafusp alfa
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06816017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06816017.